Emerging Industries and Their Insurance Needs

Joseph Ziolkowski, CEO of Bermuda-based Relm Insurance, believes that emerging industries such as climate tech, biotech, and artificial intelligence (AI) could offer solutions to some of the world's most pressing challenges, including climate change and political instability. However, these startup companies often struggle to find the investment and insurance coverages they need, presenting a significant opportunity for insurance brokers.

Focusing on Alternative Therapeutics

One area that Ziolkowski is particularly interested in is alternative therapeutics, especially the use of psychedelic drugs. Insurance Business asked him why he became interested in this field from an insurance and risk perspective.

“It was really about acknowledging the important advancements in an emerging area that could potentially change the way people approach certain medical treatments,” he said. Ziolkowski pointed out that traditional clinical treatments are often ineffective for neurological diseases such as PTSD, eating disorders, and substance abuse. Psychedelics have the potential to create significant improvements in the treatment of these disorders.

Investment in Psychedelic Drugs

There is a substantial amount of funding moving into the field of alternative therapeutics. Ziolkowski noted that sophisticated institutional investors are putting money into early-stage companies working with substances like psilocybin, MDMA, ketamine, DMT, and Ayahuasca. These substances, often known as controlled or illicit drugs, are being used to make critical advancements in treating debilitating diseases.

Global Regulatory Frameworks

Around the world, the regulatory framework for the medical use of psychedelic drugs is evolving rapidly. For instance, Alberta in Canada was the first province to decriminalize certain aspects of psychedelic compounds. In the United States, two states have made significant progress in legalizing or decriminalizing these substances. There are also 25 state referendums in the US considering how drugs like psilocybin and MDMA can be used to treat specific diseases.

Australia has also made significant strides by reclassifying MDMA and psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled drug), allowing their clinical use by psychiatrists. Similar legislative advancements are being considered by governments worldwide.

The Need for Insurance

With this momentum and the influx of funding from institutional investors, traditional pharmaceutical companies are beginning to invest in and acquire companies in early-stage clinical trials for psychedelic compounds. These startups will need insurance to operate effectively.

Ziolkowski explained that one of the main uses of insurance capacity is for companies in early-stage clinical investigations of substances like MDMA and psilocybin. Insurance is crucial for these companies to attract medical experts and other industry players to their clinical trials and boards.

Directors and Officers Liability Insurance

A significant concern for professionals being asked to serve on the boards of these companies is personal liability. Professionals are unlikely to accept board positions without directors and officers (D&O) liability insurance. This insurance protects them from personal liability while serving on a company's board.

Ziolkowski emphasized that a primary benefit Relm Insurance provides is substantive coverage for directors and officers liability. This insurance allows companies to bring on experts and professionals, which adds credibility and capability to their operations. It also satisfies investor concerns, enabling these companies to raise more capital and extend their clinical trials.

Relm Insurance's Role

Relm Insurance, with its 50 employees spread across locations like Miami, London, and Dubai, specializes in coverages for emerging industries. The company's focus on alternative therapeutics and the insurance needs of startups in this sector highlights the importance of D&O liability insurance.

By providing this coverage, Relm Insurance helps these companies attract the talent and investment they need to succeed. As these companies work towards significant medical advancements, having the right insurance in place is crucial for their growth and development.

The Bigger Picture

The challenges faced by emerging industries in securing investment and insurance coverage are significant. However, companies like Relm Insurance play a vital role in supporting these industries by offering the necessary insurance products. This support enables startups to focus on innovation and development, ultimately contributing to solving some of the world's most pressing problems.

The intersection of emerging industries like climate tech, biotech, and AI with the insurance sector presents both challenges and opportunities. Joseph Ziolkowski and Relm Insurance are at the forefront of addressing these challenges, particularly in the field of alternative therapeutics. By providing essential insurance coverages, they help startups attract investment and talent, driving progress and innovation in areas that have the potential to transform the way we approach some of the world's most significant issues.

Share On :